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This report details an experience with the North Carolina Division of Public Health 
Department of Health and Human Services (Communicable Disease Branch). The 
Communicable Disease branch works to unite local, state, and federal health agencies to 
monitor outbreaks, public health investigations, and health departments in the region. 
Real-time surveillance for the state is completed using the North Carolina Electronic 
Disease Surveillance System (NC EDSS), which requires state health officials to report 
various diseases for epidemiologic data and monitoring. Miscommunications over 
laboratory results and disease classification via the electronic-based reporting prompted 
the creation of a guide for laboratory interpretation of enteric pathogens for field use in 
North Carolina Health Departments. The guide was designed for quick reference in day-
to-day use and in the hopes of providing resources for nurses across the state to better 
aid in disease classification and provide more reliable epidemiologic data. This guide 
serves as the capstone project. 
 
In addition to work completed on enteric pathogens, the student generated an online 
survey linked to a database for a Zika Virus Registry in order to track infected mothers, 
their pregnancy progress, and infant health. This database consolidates information about 
Zika virus outbreaks across North Carolina and also generates reports to assist with 
tracking and categorizing cases and data points of interest. 
 
The student assisted in updating templates used for survey outbreaks and disease 
classification for the North Carolina Communicable Disease Manual. The student also 
had the opportunity to participate in outbreak investigations regarding Naegleria fowleri, 
Escherichia coli O157, and Salmonella.  
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Chapter 1 - Field Experience Scope of Work 
The Field Experience took place at the North Carolina Department of Health and Human 
Services on 225 North McDowell Street in Raleigh, NC 27603. The preceptor was Nicole 
Lee, MPH, a Foodborne Epidemiologist in the Communicable Disease Branch of the 
North Carolina Division of Public Health. North Carolina’s health departments are 
managed by the local county, with the state overseeing results from all the individual local 
departments and aiding whenever necessary.  
 
The primary focus of this Field Experience was to help create a guide for the laboratory 
interpretation of enteric pathogens. The guide is a practical resource to address 
miscommunicating results interpretations and to consolidate resources in order to 
minimize time spent verifying disease classification, testing methodology, control 
measures, etc. The guide include 
s resources for: case definitions, control measures, and necessary reports for the most 
common reportable pathogen in North Carolina (to maintain brevity the number of 
pathogens addressed in the final document is limited to the most common). Background 
information for each disease is also provided, including symptoms, incubation period, 
duration of illness, and communicability.  
 
The externship encompassed additional projects such as developing an online survey 
linked to the Zika Virus Database to help track and gather information regarding Zika virus 
outbreaks in the United States and assisting with disease outbreak investigations within 
the state. Disease outbreak investigations included developing, consolidating, and 
researching educational points for public statements regarding a Naegleria fowleri 
outbreak in North Carolina and interviewing individuals associated with a Salmonella 





Chapter 2 - Objectives and Activities 
 Learning Objectives: 
1. Apply knowledge and experience from KSU Doctor of Veterinary Medicine and 
Master of Public Health programs to real-world situations and contribute 
successfully to the Communicable Disease Branch  
2. Expand knowledge on communicable disease, state testing guidelines, and 
criteria for reporting various diseases with North Carolina.  
3. Understand the protocols and actions taken by state departments of health in 
communicable disease outbreaks to better prepare for a career in public 
veterinary practice. 
4. Understand the role of the Centers for Disease Control (CDC) and how federal 
and state guidelines contribute to disease recognition, tracking, containment, 
and public health awareness. 
5. Demonstrate the value of professional development gained with the North 
Carolina Department of Health through field experience products and final 
reporting for the Master of Public Health degree. 
 Activities Performed 
1. Designed and implemented a guide for North Carolina nurses to assess 
communicable diseases and better report testing results to improve accuracy of 
data compiled by the state.  
 Met with representatives of the North Carolina State Laboratory to discuss 
various laboratory testing, interpretations, and editing to final document. 
 Met with representatives of North Carolina Health Department (nurses and 
epidemiologists) to discuss difficulties with data entry, interpretation of 
laboratory results, and editing to final document. 
2. Developed an outbreak investigation survey template (SurveyMonkey) that could 
be utilized as a base construct for future outbreak investigations within the state to 
minimize response time to future outbreaks. 
3. Assisted with developing a plan to transfer outbreak investigation data in the 
National Outbreak Reporting System (NORS) from manual to direct input. 
 This project was ultimately abandoned after initial groundwork due to the 
current departmental structuring. Outbreak data is shared through the 
public health division at North Carolina (details on respiratory, sexually 
transmitted diseases, enteric pathogens, etc.). The enteric department had 
hoped to improve collection of outbreak investigation data by consolidating 
the systems to direct input; however, as this would only apply to enteric 
pathogens, it would potentially interfere with templates designed for multi-
departmental use. This would create a system that would require double 
data entry, which would eliminate the entire purpose of switching to a more 
direct system.  
4. Developed and transcribed a Zika Outbreak Survey to an online template to assist 
the CDC in collecting information regarding Zika exposure within North Carolina.  
5. Attended the State Laboratory for Public Health to shadow processing and testing 
of rabies suspect submissions. 
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 Previous Rabies vaccination status and personal protective equipment 
were required for entry to the laboratory. There the student was able to 
partake in the testing process of rabies sampling and testing including 
practicing appropriate safety measures, brain extraction techniques from 
various species (ranging from bats to cows), preparing appropriate slide 
specimens from cerebellar and brain stem samples, slide staining, and 
result interpretation. The laboratory uses Direct Fluorescent Antibody 
(DGA) testing for all rabies submissions. Rabies submissions for the day 
are given unique barcodes and assessed for risk prior to handling. The 
positive and negative control slides are prepared from previous lab 
submissions and used to compare results to. If a result is positive, additional 
testing would be performed to identify the rabies type variant. All positive 
tissue samples are permanently stored and logged for the state and CDC 
records.  
6. Participated in outbreak investigations including conference calls, preparing talking 
points for the public, and conducting interviews for the department. 
 Participated in conference calls that included discussion and planning with 
local health department staff, hospital staff, health care facility staff, and 
CDC representatives. Some cases involved additional discussions with city 
planning and water engineers. Examples of conference calls include: 
• E. coli O157 outbreak amongst campers at a primitive camping site 
• Multi-state Salmonella spp. outbreak 
• N. fowleri outbreak in North Carolina 
 Prepared talking point documents and researched educational points for 
brochures and public announcements regarding the N. fowleri outbreak. 
 Conducted interviews utilizing the National Hypothesis Generating 
Questionnaire on behalf of the CDC and North Carolina to help determine 
potential causes for a multi-state outbreak of Salmonella spp. 
 Participated in on-call support for rabies and other communicable disease 
with the state veterinarian and epidemiologists. Rabies prevention and 
control within the state requires assessing animal and human exposures, 
referring cases, and testing suspect animals for disease. Referral calls can 
receive direct guidance from state authorities on how to handle suspect 
cases, which contributes to accurate monitoring and response.  
7. Updated Investigation Steps for communicable diseases (including Listeriosis, 
Salmonellosis, Trichinosis, and Vibriosis) on the North Carolina State Department 
website for public reference.  
 
 Products Developed 
1. Guide to the Laboratory Interpretation of Enteric Pathogens – the capstone project 
to be described below in Chapter 3; involved integration across departments and 
with the state laboratory. 
 
2. Zika Registry Database – the student assisted with creating a Microsoft Access 
database for the CDC Zika Registry forms necessary to follow Zika suspect, 
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probable, or confirmed maternal and infant cases. The database allowed for forms 
to be consolidated in one place and for the generation of reports based on various 
variables contained within each form (see Chapter 4). The student helped to 
develop the necessary variables, functions, and relationships to provide a working 
database that could track and categorize data as appropriate. The student also 
entered data from the various Zika cases reported across the state of North 
Carolina. 
 
3. N. fowleri talking points and public outreach information (see Chapter 4). 
  








Appropriate surveillance and reporting for communicable diseases is vital for public health 
epidemiology and appropriate responses to protect the public. Epidemiology reporting is 
key to a state’s ability to detect outbreaks rapidly, with enhanced technology capacity 
(e.g. automated electronic laboratory-based reporting, cluster-detection software, 
geocoding, etc.) being a primary method to improve surveillance within states (Hadler and 
others 2015). North Carolina developed the North Carolina Electronic Disease 
Surveillance System (NC EDSS) as an incentive for health departments to move towards 
online surveillance of diseases within the state. NC EDSS is a part of the Public Health 
Information Network (PHIN) and it connects the Department of Public Health, 86 local 
health departments (LHDs), eight HIV/STD Regional Offices, and the Department of 
Environment Health and Natural Resources (DENR) (“NC EDSS”, n.d.). The system 
allows better case reporting, outbreak management, automatic receipt of laboratory 
reports, and pre-set statistical reports that facilitate outbreak management. 
 
The North Carolina Department of Public Health, Communicable Disease Branch, located 
in Raleigh, North Carolina utilizes the NC EDSS for reporting of communicable enteric 
diseases. Disease surveillance in the state involves active collection, analysis, and 
interpretation of disease cases that often begins with physicians, school administrators, 
child care operators, medical facilities, and restaurant operators reporting cases or 
suspected cases to their local health department (NC Health & Human Services, n.d). 
Local health departments in turn then report the results to the NC Division of Public Health 
for further analysis. The Communicable Disease Manual lists diseases that are reportable 
in North Carolina with case definitions established by the Council of State and Territorial 
Epidemiologists (NC Health & Human Services, n.d.).  
 
Difficulties with electronic systems still exist, with one of the more pertinent issues within 
the state being incorrect data entry. This has caused diseases to be logged 
inappropriately, which leads to incorrect data or lost data points. Reporting errors during 
infectious disease outbreaks can have a substantial impact on result accuracy, especially 
if the errors are not accounted for statistically (White & Pagano, 2010). Further difficulties 
reported in other states include first line responders being unaware of which diseases 
need to be reported or which department is responsible for the reporting (“Mandatory 
Reporting”, 1990). 
 
The project designed to help rectify this situation was the creation of a “Laboratory Guide 
to the Interpretation of Enteric Pathogens.” This guidebook was intended as a quick in-
field reference for healthcare professionals responsible for logging initial confirmed 
disease cases to help with appropriate categorization for those first responders and 
reporters within the state. It also highlights which diseases should be reported 
immediately, the turnaround time for laboratory results, and additional resources should 





Research was conducted via consolidating resources available from both the Centers for 
Disease Control and Prevention and the North Carolina Department of Public Health. This 
included general resources for each communicable disease from the CDC website (CDC 
“Diseases & Conditions”, 2017) and state requirements for reporting from the North 
Carolina Division of Public Health Communicable Disease Manual (NC Department of 
Health & Human Services, 2017). In addition, to reduce mistakes, resources and 
examples were provided to assist health professionals initiating a report to accurately and 
efficiently search state forms for identifying disease classifications. These example 
documents were provided by the State Department.  
 
Feedback & Recommendations 
Initial instructions and recommendations were provided by the head nurses at the State 
Department of Public Health who described the general confusion and errors they noted 
from interactions with local health departments. 
 
Feedback for the initial product was positive, but requests were made to shorten the 
original document (such as removing less common reportable pathogens such as Vibrio 
spp.). Examples of actual laboratory results were added in addition to brief reporting 
descriptions. This was to help provide examples of common reporting errors. For 
instance, some state laboratory results will have “bacterial culture” listed on their forms 
that report a polymerase chain reaction (PCR) test. This would lead to the PCR results 
incorrectly being logged as a culture result.  
 
The rough draft of the original guidebook was then reviewed by the state nurses and also 
again by representatives at the State Laboratory of Public Health. Editing 
recommendations included agreement with shortening of the initial length and also 
additional information regarding the type of laboratory testing available for each pathogen. 
They also requested additional information regarding testing and turnaround times to help 
ease communication with local health departments. Lastly, they requested that tests not 
performed at the State Laboratory be removed from the guide to decrease confusion.  
 
Final  
The final guidebook begins with a brief introduction of basic testing methods and guides 
that have previously not been available to health officials. It also introduces the testing 
methods utilized by the State Laboratory and various turnaround time for tests within state 
laboratories and from the CDC. It then proceeds to provide examples of keywords used 
in State Laboratory results that health departments can use to identify the type of testing 
utilized for reporting. A generalized table is provided to summarize the most common 
North Carolina reportable enteric pathogens.  
 
After the introduction, the guidebook is organized alphabetically within pathogen 
categories (i.e. “bacteria”, “virus”, and “parasite”). Each pathogen has a one to two page 
summary that describes the exposure, symptoms, testing methods, and communicability 
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of the disease. There is also a quick reference side panel for laboratory testing and 





Chapter 4 - Additional Products 
Product 2: Zika Registry Database 
 
The student was asked to take CDC forms available to state departments for the reporting 
of Zika Virus infections and to duplicate the forms on an online database via Microsoft 
Access. These forms included a Mother’s Health Assessment, Assessment at Delivery 
(Infant), Infant Health Follow Up Assessments, Provider Tracking Information, 
Completion Progress, and Zika Laboratory Results (Mother/Infant) (see Appendix 2).  
 
These databases were then able to be compiled into three reports – one for mother’s 
results and follow up information, one for infant’s results and follow up information, and 
one to auto-generate follow-up dates so that infants could better be tracked and care-
givers contacted during the appropriate times.  
 
Every question on each form had to be reformatted and tied to the State ID for that case 
on the online database questionnaire (see Figure 1.1). This State ID had to remain 
constant across multiple forms so that when reports were generated, the same mother 
and child were linked across forms. These variables would then convert into digital 
version of the paper forms, allowing for input of the paper forms into the online database 
with ease.  
 




Once forms were generated via Access, the program could also be utilized to generate 
reports to analyze the data or to provide additional information on when retesting would 
be required. This was important for follow-up and tracking Zika outbreaks within the state, 
as mothers would need to be contacted after initial exposure for additional follow-up 
reports. The database could generate reports (see Figure 1.2) and future follow-up dates 
for certain ID numbers, which would ultimately improve tracking of the disease within 
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North Carolina. It was hoped that it could eventually generate automatic follow-up 
responses with various ID numbers to eliminate human error or forgetfulness associated 
with case tracking. The following example report shows how from the estimated delivery 
date (EDD), appropriate dates for follow up forms such as the Maternal Health History or 
acknowledgement by the department can be generated.  
 
Figure 1.2 Example Report 
 
 
Product 3: N. fowleri Talking Points 
 
The student had the opportunity to participate in a Naegleria fowleri outbreak (Primary 
Amoebic Meningoencephalitis or PAM). The case was unique in that it involved the death 
of an Ohio native who was exposed while visiting North Carolina. This led to a combined 
effort across states and with the CDC to identify the risk of N. fowleri infections associated 
with the exposure at a whitewater recreational facility in North Carolina.  
 
This outbreak investigation was interesting in numerous ways. First, due to the multiple 
states involved and the rareness of the disease (only 111 cases have been reported in 
the U.S. from 1962-2008), communication had to be facilitated between multiple state 
departments and national facilities (Yoder and others, 2010). Initial talking points were 
adapted from publications utilized in Florida during a similar outbreak in 2014 (Weister, 
2014). Initial investigation involved narrowing down the point of exposure of the patient, 
who had died from the infection after leaving North Carolina. At this time, the only 





N. fowleri is an ubiquitous free-living amoeba found in most warm freshwater in the United 
States that can cause an often-times fatal disease called primary amebic 
meningoencephalitis (PAM) (CDC “Parasites – N. fowleri”, 2017). Infection usually occurs 
when infected water is forced up the victim’s nostrils, allowing the amoeba to push past 
the cribriform plate and invade the brain. This presumed route of infection helped to limit 
the investigation for the exposure location to a site that involved warm freshwater and 
also potential for water being forced up nostrils.  
 
Identification of a potential exposure location directed field investigators to the Center to 
take water samples for further testing. People from multiple state who were potentially 
exposed also had to be notified, and the center was temporarily closed during the 
investigation. The highly publicized nature of the case within North Carolina led to new 
legislation being rapidly proposed for the regulation of whitewater facilities within the 
state, which made prudent and accurate responses for the public even more important 
(Foster & Bruno, 2016). While the center did standard testing for coliforms in the water 
there were no state recommendations or protocols at the time for water sites to test for 
N. fowleri in water. The student was asked to prepare talking points and frequently asked 
questions (FAQs) that could be distributed throughout the North Carolina State 
Department and be utilized to answer news medias’ and the public’s concerns. 
 
Further investigation at the associated facility found that the facility had unique features 
that made it prone to Naegleria fowleri growth, as all eleven water samples from the park 
were consistently positive for high amounts of the amoeba (Foster & Bruno, 2016). This 
made it a unique situation to which the original CDC control measures could not be 
applied, and consequently talking points and FAQs had to be adjusted accordingly (see 
Appendix 3). The Whitewater facility referenced a paper with its public response 
regarding water disinfection via ultraviolet light and how they followed such practices at 
their facility (Foster & Bruno, 2016; Sarkar & Gerba, 2012). This prompted research into 
how effective UV light penetration would be given their current water supply and algal 
growth. It was ultimately deemed after consultation, that the UV disinfection would be 
inadequate given the unique algal growth situation at the park that promoted high levels 
of the amoeba in its waters (especially when compared to the source from which the park 
drew its water). Even the initial paper suggested that factors such as organism 
concentration, disinfectant concentration, temperature, pH, and interfering substances 
could impact the efficacy of both chlorine and UV light as N. fowleri disinfectants (Sarkar 
& Gerba, 2012). Additional research has also shown that biofilms in field experiments 
may be more resistant to chlorine disinfection, allowing N. fowleri survival despite chlorine 
levels found to be effective in the laboratory (Miller and others, 2015).  
 
The structure of the pools within the park promoted algal growth, which was believed to 
contribute to a biofilm and to create an environment suitable to excess N. fowleri growth. 
Ultimately, consultation with water engineers and other experts prompted the decision to 
temporarily close the whitewater rafting at the facility until a time where the engineering 
could be redone. In response, the facility drained the upper level pools to thoroughly clean 
algal growth to better improve efficacy of their filtration system.   
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Chapter 5 - Core Competencies 
 The courses required for the Masters of Public Health program at Kansas State 
University, and those courses that augmented my education from the Doctor of Veterinary 




 These courses gave me a better understanding of the analysis necessary for the 
information gathered. It helped me to have an appreciation of why it was vital that we had 
accurate reporting from local health departments. It also helped me understand the 
projects that other students were working on during my stay with the North Carolina Public 
Health Department, especially in regards to survey analysis of Salmonellosis cases in 
North Carolina. At the time of my field experience project, I had not completed all of my 
biostatistics courses; however, I still was able to apply what I had learned regarding study 
designs and quantitative analysis to both designing programs for data analysis and 
interpretation of research papers.  
 
Environmental Health Sciences 
 This course was beneficial in assessing risk analysis and the level of appropriate 
exposure of various chemicals. In my field experience, it was useful for both 
understanding risk associated with various laboratory tests and also with 
recommendations made for water sanitation during the Whitewater Center N. fowleri 
outbreak. Sanitation methods had to be recommended that would be both efficacious yet 
safe for the employees and future guests of the park. The course helped to provide a 
broader insight into public health and how human and animal health are not always linked 
to diseases, but also to toxins and occupational hazards.  
 
Epidemiology 
 Epidemiology was one of the most helpful core competencies for my field 
experience, as many of the projects I was involved with were essentially applied 
epidemiology. Drawing results from clusters of disease outbreaks such as identifying a 
source of infection or assessing which groups were most at risk relied on epidemiology 
knowledge. This was particularly apparent in all outbreak investigations – especially when 
localizing the cause of Salmonella and E. coli outbreaks.  
 Gathering data ethically and a manner that both helped the Health Department 
and the individuals involved took recognition of epidemiologic patterns and knowledge of 
how epidemiologic data can be utilized legally.  
 Identifying past epidemiologic patterns was also useful in helping to project future 
problems or incompetency within the state department or recurring outbreak patterns 
within the state.  
 
Health Service Administration 
 This course greatly impacted my field experience as much of what I had learned 
from public communication needed to be applied for communication with the public. For 
instance, I had to simplify my original talking points provided during outbreaks to make 
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the information more accessible for all educational levels. This was a key discussion we 
had during MPH 720.  
 Recognizing the bureaucracy associated with public health systems and how local 
health department decisions are intertwined and affect the state department was also 
crucial for organizing my capstone project. It was also important to realize how healthcare 
employers do not necessarily communicate with the laboratory component of healthcare, 
which can greatly impact epidemiologic reporting and management on the state level.  
 
Social and Behavioral Science 
 This course was beneficial in how it allowed us to develop talking points and 
answer concerns of the general public – making for an effective intervention before panic 
could affect the public (especially during the N. fowleri outbreak). It also provided 
excellent recommendations for addressing the public’s concerns in an efficient and 
professional manner. This was important as we had to reformat our talking points with 
growing information regarding the unique factors of the Whitewater center that made our 
initial assumption regarding N. fowleri risk change. It was important to be honest and 
forthcoming with the public, and MPH 818 helped me build the necessary communication 
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Laboratory Guide to 
Enteric Pathogens
Division of Public Health, Communicable Disease Branch 






With  advancements  in  laboratory  techniques  and  the  importance   of  laboratory 
results  on  disease   classification,   proper  interpretation  of  laboratory  results  is 
increasingly important for determining public  health action. 
Information  regarding  testing  and  shipping   requirements  for  the  State  Laboratory 
of  Public  Health  (SLPH)   can  be  found  in  SCOPE  –  A  Guide  to  Service  at: 
http://slph.ncpublichealth.com/doc/administration/SCOPE‐Final‐Rev‐30116.pdf  
The  purpose   of  this  document   is  to  provide  North  Carolina  health  department 
employees with a practical guide   to  interpretation of  reportable  enteric pathogen 
laboratory  results. Pathogen  summaries will be provided  along with discussion  on  
common errors  in  regards  to  lab  results and disease classification. This guide  is by 



















 Stool  –  the  preferred  sample  due  to  the  fact  it  is  non‐invasive  and  can  provide  a  wealth  of 




































































































Once  submitted,  it  generally  takes  between  7‐10 work  days  (“turnaround  time”)  for  Enteric  reference 
identifications and clinical cultures.  
In  North  Carolina,  public  health  utilizes  a  courier  system  that  ships  samples  to  Mocksville,  NC  to 
minimize costs. This means it can take additional days before samples arrive to the state laboratory (up to 
three  days  if  over  the weekend).  Testing  can  take  a  few  additional  days  once  samples  arrive, which 
accounts for the wide range in turnaround times. Pathogens do not always “read the textbook” on growth 
or other laboratory tests and it can be difficult to predict when exactly results will be available.  






















PCR  testing  tends  to  have  a  faster  turn‐around  time  than 
culture,  and  is  thus  preferred  in  a  clinical  setting  because  it 
allows the patient to be managed earlier in presentation.  
PCR identifies DNA. This DNA could be from a viable (alive) 






pathogen  through  the  use  of  antibody  and  color  change. 
Generally  used  to  detect  viral  pathogens  or distinguish  STEC 
toxins. Sera are the preferred sample. 
Immunofluorescent Assay  (IFA):  tests  that bind antibodies 
to  a  fluorochrome,  which  produces  fluorescence  under 
ultraviolet light. Immunofluorescence can be detected by direct 
(DFAs) or  indirect methods, with pathogen‐specific antibodies 
binding  to antigens  located  in  tissue or cell samples. Generally 
used to detect viral pathogens with sera the preferred sample.  
Pulsed‐field  gel  Electrophoresis  (PFGE):  a  test  that 
separates DNA molecules by applying an electric field  to a gel 
matrix. The  size  of  the molecules dictates  how  far  they move 
across the gel. It is generally used for genotyping (determining 
specific  genetics),  and  the  CDC  recommends  its  use  for 












































 Distinguishes  between  species  (e.g. 
Campylobacter  jejuni vs. Campylobacter 













 Multiple  pathogens  being  tested  for 
at once indicates PCR 
 TAG or taq mentioned 



































































































































Prioritizing Disease Investigations 
All  pathogens  listed  are  important  and  need  to  be 























Most enteric pathogens in this guide must be 
reported within 24 hours. Botulism must be 



























PATIENT:    ORDERING PHYSICIAN: 
 
 























Adenovirus 40, 41 
Not reportable 
Norovirus 




  Enterohemorrhagic E. coli (EHEC) 
Shiga-like toxin gene (stx1) 
Shiga-like toxin gene (stx2)  
Reportable 
 
Enteropathogenic E. coli (EPEC)  
Not reportable – has virulence markers  
but does not produce shiga toxin 
 
Enterotoxigenic E. coli (ETEC)  
Not reportable 
 
Enteroinvasive E. coli (EIEC)/Shigella  
Reportable- Shigella 
 
(EIEC) Salmonella enterica 
Reportable 
 
Campylobacter jejuni  
Reportable 
 
Vibrio parahaemolyticus  
Not reportable 
 






  Giardia lamblia 
Not reportable
































































































































































































































































































































Signs & Symptoms   Duration  Food Sources  Diagnostic 
Test 

















































































































































































































Note that only toxigenic 






Ingestion of fecal contaminated water or food 
source; poor sanitation; rarely undercooked 
shellfish 
Incubation Time: 2-3 days 






























































ETEC, EPEC, EAEC, EIEC, and DAEC types of E.coli, while pathogenic, are generally 








































































Ingestion of undercooked beef (viz. hamburger), 
unpasteurized milk and juice, raw fruits and 
vegetables (viz. sprouts) 
Incubation Time: 1-8 days 

















































































Consumption of contaminated foods such as 
eggs, poultry, meat, unpasteurized milk, juice, or 
cheese; contact with pet reptiles 
Incubation Time: 6-48 hours 


















































































Fecal-oral exposure to contaminated food or 
water; poor hygiene  
Incubation Time: 1-2 weeks 















































































Exposure to raw produce, contaminated drinking 
water, uncooked foods; poor hand hygiene 
Incubation Time: 4-7 days 

















































































Consumption of undercooked or raw seafood 
such as shellfish (especially oysters) or wounds 
exposed to brackish or salt water 
Incubation Time: 24 hours 














































































Consumption of unpasteurized milk, 
unpasteurized soft cheeses, and read-to-eat deli 
meats 
Incubation Time: 9-48 hours 










































































Consumption of undercooked or raw seafood 
such as shellfish (especially oysters) 
Incubation Time: 1-7 hours 











































































Exposure via fecal-oral route or from direct 
contact with infected humans or animals 
Incubation Time: 2-10 days 
Duration of Illness: 3 weeks; may be remitting and 














































































Exposure via consumption of contaminated food 
or water, or contact with contaminated soil 
Maturation Time Outside Host: 7-13 days 
Duration of Illness: Variable; may be remitting and 

















Main Points to Remember 
 
 Control measures should be applied to 
all confirmed, probable, and suspect 
cases! 
 
 PCR detects DNA – from both alive 
and potentially dead organisms! 
 
 





Lab turnaround time can 
take weeks.  
Be patient with your 
laboratories!  Call the 
foodborne team if 









Lab results that 
read “culture” 
may actually be 
PCR or EIA results. 
Double check!  
E. coli Infections: 




stool, urine, synovial 
joint fluid, vomitus, 
etc. 
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Version 7/9/2016 
Pregnancy and Zika Virus Surveillance—Infant Follow-Up Form 
These data are considered confidential and will be stored in a secure database at the Centers for Disease Control and Prevention 
Please return completed form via SAMS or secure FTP—request access from ZIKApregnancy@cdc.gov  
  The form can also be sent by encrypted email to this address or by secure fax to 404-718-1013 or 404-718-2200     
Infant follow up:    2 months    6 months    12 months          
 









IFU.6. Sex:    Male       Female  
           Ambiguous/undetermined 
IFU.7. Infant Death:      No      Yes, date _____/_____/____  or  Age at death ________   Unknown  
IFU.8. Weight: 
_______grams or ____ lbs_____ oz 
IFU.9. Length:  
_______  cm   or  _______ in   
IFU.10. Head circumference:  
_______  cm   or  _______ in   
IFU.11. Infant findings for corrected age at examination: (For infants born preterm, please account for 
corrected age: chronological age minus weeks born before 40 weeks’ gestation)  
 
Check all that apply  
 Microcephaly (head circumference <3%ile)                        Excessive and redundant scalp skin                  
 Arthrogryposis (congenital joint contractures)                   Congenital Talipes Equinovarus (clubfoot) 
 Hypertonia/Spasticity                Hyperreflexia                  Irritability                   Tremors                    
 Splenomegaly                              Hepatomegaly                Skin rash                    Microphthalmia   
 Absent red reflex                        Swallowing/feeding difficulties                           Other                     




IFU.13. Development assessment for corrected age at examination: (For infants born preterm, please account 
for corrected age: chronological age minus weeks born before 40 weeks’ gestation) 
 Normal     Abnormal   Unknown   
 
IFU.14. If developmental delay, in what area? Please check all that apply 
 Gross motor      Fine motor      Cognitive, linguistic and communication      Socio-Emotional 
Special Studies Since Last Follow-up 
IFU.15. Imaging study:   Cranial ultrasound      MRI      CT     Other _____________   
 Not Performed     Unknown  
IFU.16. Date: _____/_____/_____       
 
IFU.17. Findings: check all that apply 
 Microcephaly        Cerebral (brain) atrophy       Cerebellar atrophy                 Intracranial calcification       
 Ventricular enlargement        Lissencephaly      Pachygyria                                Hydranencephaly                   
 Porencephaly      Abnormality of corpus callosum                             Other abnormalities  
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Mother’s State/Territory ID ________________                                                           
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IFU.19. Imaging study:   Cranial ultrasound      MRI      CT     Other ______________  
 Not Performed     Unknown 
IFU.20. Date: _____/_____/_____       
 
IFU.21. Findings: check all that apply 
 Microcephaly        Cerebral (brain) atrophy      Cerebellar atrophy                  Intracranial calcification       
 Ventricular enlargement       Lissencephaly      Pachygyria                                Hydranencephaly                   
 Porencephaly       Abnormality of corpus callosum                             Other abnormalities  
IFU.22. (please describe below)   
 
 
IFU.23. Hearing screening or re-screening:   Not performed   Performed   Unknown   
IFU.24. If performed: Date: ____/____/____ IFU.25.  Pass    Fail or referred,  
IFU.26. Please describe  
       
 
IFU.27. Audiological evaluation:    Not performed   Performed   Unknown   
IFU.28. If performed: Date: ____/____/____ IFU.29.  Normal    Abnormal,  
IFU.30. Please describe 
 
 
IFU.31. Retinal exam (with dilation):       Not Performed    Performed     Unknown    
IFU.32. If performed: Date: _____/_____/_____  
IFU.33. Findings: Check all that apply:   
 Microphthalmia   Chorioretinitis    Macular pallor   Other retinal abnormalities 
IFU.34. Please describe  
 
 
IFU.35. Other abnormal tests/results/diagnosis (include dates):   No       Yes   
IFU.36. Date: _____/_____/_____ 
IFU.37. Please describe 
 
 
Health Department Information 
IFU.38. Name of person completing form: _______________________________________________________ 
IFU.39. Phone:  _______________ IFU.40. Email: ________________________  
IFU.41. Date of form completion _____/_____/____ 
Internal use only 
Date entered____/_____/_____ 
Data Entry POC Initials: ________ 
Data Entry Notes: 
Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and 
maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information 
unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this 
burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS E-11, Atlanta, Georgia 30333; ATTN: PRA (0920-1101) 
                              Registry ID _____________          State/Territory ID ___________________________ Approved 
                    OMB No. 0920-1101 
Exp. 08/31/2016 
Version 07/09/2016 
Pregnancy and Zika Virus Surveillance—Maternal Health History Form 
These data are considered confidential and will be stored in a secure database at the Centers for Disease Control and Prevention. 
Please return completed form via SAMS or secure FTP—request access from ZIKApregnancy@cdc.gov  
  The form can also be sent by encrypted email to this address or by secure fax to 404-718-1013 or 404-718-2200     
   
MHH.1. State/Territory ID:  
___________________________ 
MHH.2. Maternal Age 
at Diagnosis: _____ 
MHH.3. State/Territory reporting: ________________ 
MHH.4. County reporting: _______________________ 
MHH.5. Ethnicity:   Hispanic or Latino      Not Hispanic or Latino      
MHH.6. Race (check all that apply):   
 American Indian or Alaskan Native     Asian     Black or African-American     
 Native Hawaiian or other Pacific Islander             White           
MHH.7. Indication for maternal Zika virus testing:   Exposure history only, no known fetal abnormalities 
                                                                                              Exposure history and fetal abnormalities 
MHH.8. Date of Zika virus symptom onset: _____/_____/_____          OR        MHH.9.      Asymptomatic 
MHH.10. If symptomatic, gestational age at onset: ___________________(weeks, days) 
MHH.11. If gestational age or date not known, trimester of symptom onset _________________ (1st, 2nd, 3rd)                                                                          
MHH.12. Symptoms of mother’s Zika virus disease: (check all that apply) 
 Fever(if measured) _____oF or _____oC      Arthralgia     Conjunctivitis     Rash   
 Other clinical presentation______________________________________________________________________ 
MHH.13. If rash, check all that apply   Maculopapular    Petechial    Purpuric    Pruritic     
Describe rash distribution__________________________________________________________ 
MHH.14. Hospitalized for Zika virus disease     No      Yes      Unknown                     
MHH.15. Maternal Death      No     Yes     Unknown   If yes, describe_________________________________             
MHH.16. If yes, date of death _____/_____/_____                                          _________________________________ 
History of Exposure 
MHH.17. What was the suspected mode of Zika virus transmission?  
 Human-mosquito-human (vector)     Sexual     Other, please specify______________________   Unknown  
MHH.18. Did the woman spend time in any areas outside the US states or US territories where there was active 
Zika virus transmission during the periconceptional period or during pregnancy?  
(http://www.cdc.gov/zika/geo/active-countries.html)    
  No      Yes      Unknown      (If ‘no’ or ‘unknown’, skip to question 26) 
MHH.19. If yes, please characterize the type of travel: 
 Incoming travel (one way travel to US states from an area with active Zika virus transmission) 
 Incoming travel (one way travel to US territories from an area with active Zika virus transmission) 
 Outgoing and incoming travel (roundtrip from US states to an area with active Zika virus transmission) 
 Outgoing and incoming travel (roundtrip from US territories to an area with active Zika virus transmission)        
If incoming or outgoing travel, please list location and dates of travel:  
MHH.20. Country of exposure (1)   
_____________________________ 
MHH.21. Start Date   ____/_____/_____  
    Start date is same as LMP 
End Date  ____/_____/_____ 
MHH.22. Country of exposure (2) MHH.23. Start Date  ____/_____/_____ End Date  ____/_____/_____ 
                              Registry ID _____________          State/Territory ID ___________________________ Approved 
                    OMB No. 0920-1101 
Exp. 08/31/2016 
Version 07/09/2016 
Pregnancy and Zika Virus Surveillance—Maternal Health History Form 
These data are considered confidential and will be stored in a secure database at the Centers for Disease Control and Prevention. 
_____________________________     Start date is same as LMP 
MHH.24. Country of exposure (3)  
_____________________________ 
MHH.25. Start Date  ____/_____/_____ 
    Start date is same as LMP 
End Date  ____/_____/_____ 
MHH.26. Was the Zika virus exposure within the 50 states, DC, or territories?     No      Yes      Unknown  
If yes, separately list each state or territory where Zika virus exposure occurred, and dates of possible exposure: 
MHH.27. State or territory 1  
______________________________ 
MHH.28. Start Date _____/_____/_____    
 Start date is same as LMP  
End Date  _____/_____/_____ 
 Still at location  
MHH.29. State or territory 2  
______________________________ 
MHH.30. Start Date  _____/_____/_____    
 Start date is same as LMP  
End Date  _____/_____/_____ 
 Still at location  
MHH.31. State or territory 3  
______________________________ 
MHH.32. Start Date  _____/_____/_____    
 Start date is same as LMP  
End Date  _____/_____/_____ 
 Still at location  
MHH.33. If suspected mode of transmission is sexual, was the pregnant woman’s sexual partner(s): 
  Male      Female     Please check all that apply     
MHH.34. Did any sexual partner(s) have an illness that included fever, rash, joint pain, or pink eye during or within 
2 weeks of spending any time in an area with active Zika virus transmission?     
  No      Yes      Unknown 
MHH.35. If yes, was there unprotected sexual contact while partner(s) had this illness?     
  No      Yes      Unknown 
MHH.36. Did partner have a test that demonstrated laboratory evidence of Zika virus infection?        No      Yes    
  Unknown 
Maternal Health History (Underlying maternal illness) 
MHH.37. Diabetes    No    Yes   Unknown     
MHH.38. Maternal Phenylketonuria (PKU)   No    Yes    Unknown                    
MHH.39. Hypothyroidism   No    Yes    Unknown     
MHH.40. High Blood Pressure or Hypertension   No    Yes    Unknown                    
MHH.41. Other underlying illness(es):  No    Yes    Unknown                 
MHH.42. If yes, specify: ____________________________________________________ 
Pregnancy Information 
MHH.43. Last menstrual period (LMP): 
_____/_____/_____ 
MHH.44. Estimated delivery date (EDD):  
_____/_____/_____ 
MHH.45. Estimated delivery date based on (check all that apply): 
 LMP     U/S (1st trimester)     U/S (2nd trimester)          U/S (3rd  trimester) 
 Other, specify ______________________________________ 
OB 
History:    
MHH.46. # pregnancies (including current pregnancy) _____  
MHH.48. # miscarriages   _____    
MHH.47. # living children  _____      
MHH.49. # elective terminations  _____ 
MHH.50. Prior fetus/infant with microcephaly:  No   Yes   Unknown     
MHH.51. If yes, cause genetic?:  No   Yes  Unknown      
MHH.52. Gestation:   Single   Twins   Triplets+ 
                              Registry ID _____________          State/Territory ID ___________________________ Approved 
                    OMB No. 0920-1101 
Exp. 08/31/2016 
Version 07/09/2016 
Pregnancy and Zika Virus Surveillance—Maternal Health History Form 
These data are considered confidential and will be stored in a secure database at the Centers for Disease Control and Prevention. 
Substance use 
during this 
pregnancy:   
MHH.53. Alcohol use:   
MHH.54. Cocaine use: 
MHH.55. Smoking:       
 No   Yes   Unknown 
 No   Yes   Unknown        
 No   Yes   Unknown         
Complications during current pregnancy 
MHH.56. Toxoplasmosis infection:        No    Yes    Unknown  
MHH.57. Cytomegalovirus infection:     No    Yes    Unknown  
MHH.58. Herpes Simplex infection:  No    Yes    Unknown 
MHH.59. Rubella infection:                   No    Yes    Unknown 
MHH.60. Syphilis infection:        No    Yes    Unknown 
MHH.61. Fetal genetic abnormality: 
 No    Yes,   MHH.62. Diagnosis _____________________  
 Unknown 
MHH.63. Gestational diabetes:  No    Yes    Unknown 
MHH.64. Pregnancy-related hypertension:  No    Yes    Unknown 
MHH.65. Intrauterine death of a twin:  No    Yes    Unknown 
MHH.66. 
Other:    No   Yes  Unknown    
MHH.67. If yes, please specify ____________________________________________________ 
  
MHH.68. Medications during pregnancy:  No   Yes   Unknown      
MHH.69. If yes, specify (please specify type and see guide for further instructions):  
 
 
Pregnancy Losses:  Please also complete pertinent sections of neonatal assessment form 
MHH.70. Did this pregnancy end in miscarriage (<20 weeks of gestation)?     
     No   Yes   Unknown     MHH.71. Date: _____/_____/_____   or  gestational age_______ weeks 
MHH.72. Please describe any abnormalities noted ____________________________________________________ 
MHH.73. Did this pregnancy end in stillbirth (intrauterine fetal demise) (≥20 weeks of gestation)?  
     No   Yes   Unknown   MHH.74. Date: _____/_____/_____    or gestational age_______ weeks 
MHH.75. Please describe any abnormalities noted_____________________________________________________ 
MHH.76. Was this pregnancy terminated?   
     No   Yes   Unknown     MHH.77. Date: _____/_____/_____   or gestational age ______ weeks 
MHH.78. Please describe any abnormalities noted _____________________________________________________ 







Check if date 







MHH.82. Overall fetal ultrasound results:      Normal       Abnormal 
MHH.83.  Reported by patient/healthcare provider    MHH.84.  Ultrasound report 
MHH.85. Head Circumference (HC) _______cm      
MHH.86.  Normal       Abnormal (by physician report)  
MHH.87. Biparietal diameter (BPD) ______cm             
MHH.88. Femur length (FL) _____cm      
MHH.89. Abdominal circumference (AC) _____cm  
MHH.90.  Symmetrical intrauterine growth restriction (IUGR) (<5% EFW) 
                  Asymmetrical IUGR (HC<FL or HC <AC) 
MHH.91. Microcephaly  No    Yes MHH.92. Intracranial calcifications  No    Yes    
MHH.93. Encephalocele  No    Yes     MHH.94. Ventriculomegaly  No    Yes    
MHH.95. Cerebral atrophy  No    Yes MHH.96. Ocular anomalies      No    Yes    
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 No    Yes 
MHH.98. Corpus callosum 
abnormalities                             
 No    Yes 
MHH.99. Arthrogryposis  No    Yes MHH.100. Lissencephaly               No    Yes 
MHH.101. Pachygyria                                  No    Yes MHH.102.Hydranencephaly       No    Yes 
MHH.103. Porencephaly             No    Yes MHH.104.Hydrops      No    Yes 
MHH.105. Ascites    No    Yes  
 MHH.106. Other  No    Yes  If yes, describe: 
 








  MHH.109. 
check  
if date 






MHH.111. Overall fetal ultrasound results:      Normal       Abnormal  
MHH.112.  Reported by patient/healthcare provider or   MHH.113.  Ultrasound report 
MHH.114. Head Circumference (HC) _______cm       
MHH.115.  Normal       Abnormal (by physician report)  
MHH.116. Biparietal diameter (BPD) ______cm             
MHH.117. Femur length (FL) _____cm      
MHH.118. Abdominal circumference (AC) _____cm 
MHH.119.  Symmetrical IUGR (<5% EFW)     Asymmetrical IUGR (HC<FL or HC <AC) 
MHH.120. Microcephaly  No   Yes MHH.121. Intracranial calcifications  No    Yes    
MHH.122. Encephalocele  No   Yes     MHH.123. Ventriculomegaly  No    Yes    
MHH.124. Cerebral atrophy  No   Yes MHH.125. Ocular anomalies      No    Yes    
MHH.110. 








 No   Yes 
MHH.127. Corpus callosum 
abnormalities               
 No    Yes 
MHH.128. Arthrogryposis  No   Yes MHH.129. Lissencephaly               No    Yes 
MHH.130. Pachygyria                                  No  Yes MHH.131. Hydranencephaly       No    Yes 
MHH.132. Porencephaly             No   Yes MHH.133. Hydrops      No    Yes 
MHH.134. Ascites    No    Yes  
 MHH.135. Other  No   Yes  If yes, describe: 
 








check if date 




MHH.140. Overall fetal ultrasound results:      Normal       Abnormal  
MHH.141.   Reported by patient/healthcare provider    MHH.142.  Ultrasound report 
MHH.143. Head Circumference (HC)_______cm      
MHH.144.  Normal       Abnormal (by physician report)  
MHH.145. Biparietal diameter (BPD) ______cm             
MHH.146. Femur length (FL) _____cm      
MHH.147.Abdominal circumference (AC) _____cm  
MHH.148.  Symmetrical IUGR (<5% EFW)        Asymmetrical IUGR (HC<FL or HC <AC) 
MHH.149. Microcephaly  No    Yes MHH.150. Intracranial calcifications  No    Yes    
MHH.151. Encephalocele  No    Yes     MHH.152. Ventriculomegaly  No    Yes    
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MHH.153. Cerebral atrophy  No    Yes MHH.154. Ocular anomalies      No    Yes    
MHH.155. Cerebellar 
abnormalities 
 No    Yes 
MHH.156. Corpus callosum 
abnormalities                             
 No    Yes 
MHH.157. Arthrogryposis  No    Yes MHH.158. Lissencephaly               No    Yes 
MHH.159. Pachygyria                                  No    Yes MHH.160. Hydranencephaly       No    Yes 
MHH.161. Porencephaly             No    Yes MHH.162. Hydrops      No    Yes 
MHH.163. Ascites    No    Yes  
 MHH.164. Other  No    Yes   If yes, describe: 
 
MHH.165. Description of abnormal ultrasound findings: 
 
 
**For additional ultrasounds or MRIs, please request a supplementary imaging form** 








check if date is 
approximated  
 
MHH.170. Overall fetal MRI results:      Normal   Abnormal  
Describe:________________________________________________________________________ 
MHH.171.  Reported by patient/healthcare provider    MHH.172.  MRI report 
MHH.173. Head Circumference (HC) ___cm          
MHH.174.   Normal       Abnormal (by physician report) 
MHH.175. Biparietal diameter (BPD) _____cm        
MHH.176. Femur Length (FL) _____cm     
MHH.177. Abdominal circumference (AC) _____cm  









MHH.179. Encephalocele  No    Yes MHH.180. Intracranial calcifications  No    Yes    
MHH.181. Ventriculomegaly  No    Yes     MHH.182. Cerebral atrophy  No    Yes    
MHH.183. Ocular anomalies      No    Yes MHH.184. Cerebellar abnormalities  No    Yes    
MHH.185. Arthrogryposis      No    Yes 
MHH.186. Corpus callosum 
abnormalities    
 No    Yes 
MHH.187. Lissencephaly               No    Yes MHH.188. Pachygyria                                  No    Yes 
MHH.189. Hydranencephaly       No    Yes MHH.190. Porencephaly             No    Yes 
MHH.191. Hydrops      No    Yes MHH.192. Ascites    No    Yes 
MHH.193. Other   No    Yes     MHH. 194. If yes, describe: 
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MHH.196. Amniocentesis performed:    No   Yes      MHH.197. If yes, date performed: _____/_____/_____  
MHH.198. If date unknown, gestational age at time of amniocentesis _____(weeks, days) 
MHH.199. Amniotic fluid Zika virus testing:   Not performed   Yes  
MHH. 200. If yes, test results:    Negative for Zika   PCR+ Zika       
MHH.201. Non-Zika infection detected:  No    Yes    
MHH. 202. If yes, what infection(s) detected_____________________________          
MHH.203. Genetic abnormality detected:  No  Yes        
MHH.204. If yes, please describe: _________________________________________________________    
For reporting additional lab results, please use lab form 
Health Department Information 
MHH.205. Name of person completing form: _____________________________________________________ 
MHH.206. Phone: _______________   MHH.207. Email: _________________________  
MHH.208. Date form completed ____/____/____  
Internal use only 
Date entered____/_____/_____ 
Data Entry POC Initials: _______ 
Data Entry Notes: 
Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the 
data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently 
valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 
1600 Clifton Road NE, MS E-11, Atlanta, Georgia 30333; ATTN: PRA (0920-1101). 
 
Version 6/20/2016 
Pregnancy and Zika Virus Surveillance—Neonate Assessment Form 
These data are considered confidential and will be stored in a secure database at the Centers for Disease Control and Prevention 
Please return completed form via SAMS or secure FTP—request access from ZIKApregnancy@cdc.gov           
The form can also be sent by encrypted email to this address or by secure fax to 404-718-1013 or 404-718-2200     








NAD.3. DOB:   
_____/_____/______ 
Live birth Stillbirth 
NAD.4. Sex:   
 Male           Female  
 Ambiguous/undetermined 
NAD.5. Gestational age at delivery:  
 ______ weeks  ______ days 
NAD.6.  Based on: (check all that apply)     
 LMP ___/___/___       
 U/S (1st trimester)     U/S (2nd trimester)        U/S (3rd  trimester)        
 Other_______________ 
NAD.7. State/Territory reporting:  _______________ NAD.8. County reporting: __________________ 
NAD.9. Delivery type:    
 Vaginal        Caesarean section     
NAD.10. Delivery complication:  No   Yes   
NAD.11. If yes, please describe: 
_______________________________________    
NAD.12. Arterial Cord blood pH (if performed): _________ 
 
NAD.13. Venous Cord blood pH (if performed): _________ 
NAD.14. Placental exam (based on path report):  No   Yes          
NAD.15. If yes,   Normal         Abruption          Inflammation        Other abnormality (please describe)  
 
 
NAD.16. Apgar score:  
1 min _______ / 5 min ________    
NAD.17. Infant temp (if abnormal): _______ oF  or ______ oC 
Physical Examination 
NAD.18. Birth head circumference:  
 _______ cm  ________ in  
NAD.19.  molding present 
NAD.20. Physican report:  Normal     Abnormal  
NAD.21. Birth weight:      
_________ grams      
_________ lbs/oz 
NAD.22. Birth length: 
_________   cm 
_________   in   
NAD.23. Repeat head circumference:                      
_______ cm  _______ in     
 <24hrs   24–35hrs   36–48hrs    >48hrs 
NAD.24. Physican report:   Normal     Abnormal                         
NAD.25. Admitted to Neonatal Intensive Care Unit:       
 No       Yes   If yes, reason: 
____________________________________________                                                     
NAD.26. Neonatal death:   No       Yes  
Date __/__/____   or age at death____________ days 
NAD.27. Microcephaly (head circumference <3%ile):  
 No       Yes 
NAD.28. Seizures:                                                             
 No       Yes 
NAD.29. Neurologic exam: (check all that apply)    
 Not performed    Unknown     Normal       Hypertonia/Spasticity     Hyperreflexia       Irritability        
 Tremors     Other neurologic abnormalities  NAD.30. (please describe below)       
      
 
NAD.31. Splenomegaly by physical 
exam:  
 No   Yes   Unknown  
NAD.32. (please describe)    
 
 
NAD.33. Hepatomegaly by 
physical exam:   
 No   Yes   Unknown        




NAD.35. Skin rash by physical exam:   
 No   Yes   Unknown        
NAD.36. (please describe) 
 
Infant’s State/Territory ID____________________   Mother’s State/Territory ID ___________________ Approved 
OMB No. 0920-1101 
Exp. 08/31/2016 
Version 6/20/2016 
Pregnancy and Zika Virus Surveillance—Neonate Assessment Form 
These data are considered confidential and will be stored in a secure database at the Centers for Disease Control and Prevention 
NAD.37. Other abnormalities identified: please check all that apply  
 Microphthalmia                                 Absent red reflex                 Excessive and redundant scalp skin  
 Arthrogryposis (congenital joint contractures)                                Congenital Talipes Equinovarus (clubfoot)   




Neonate Imaging and Diagnostics 
NAD.39. Hearing screening :  (date:____/_____/_____)   




NAD.42. Retinal exam (with dilation):       Not Performed      Performed   Unknown     
NAD.43. If performed: (date: _____/_____/_____)    
NAD.44. please check all that apply:   
 Microphthalmia      Chorioretinitis   Macular pallor   Other retinal abnormalities  




NAD.46. Imaging study:   Cranial ultrasound    MRI     CT    Not Performed     
NAD.47. (date: _____/_____/_____)                                    
NAD.48. Findings: check all that apply 
 Encephalocele       Microcephaly        Cerebral (brain) atrophy       Cerebellar abnormalities 
 Intracranial calcification        Ventricular enlargement     Lissencephaly      Pachygyria    
 Hydranencephaly     Porencephaly   Abnormality of corpus callosum     




NAD.50. Imaging study:   Cranial ultrasound   MRI     CT    Not Performed     
NAD.51.  (date: _____/_____/_____)                                    
NAD.52. Findings: check all that apply 
 Encephalocele       Microcephaly        Cerebral (brain) atrophy       Cerebellar abnormalities 
 Intracranial calcification        Ventricular enlargement     Lissencephaly      Pachygyria      
 Hydranencephaly    Porencephaly   Abnormality of corpus callosum   






Infant’s State/Territory ID____________________   Mother’s State/Territory ID ___________________ Approved 
OMB No. 0920-1101 
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NAD.54. Imaging study:   Cranial ultrasound   MRI     CT  NAD.55. (date: _____/_____/_____)                                    
 Not Performed     
NAD.56. Findings: check all that apply 
 Encephalocele      Microcephaly        Cerebral (brain) atrophy       Cerebellar abnormalities  
 Intracranial calcification        Ventricular enlargement     Lissencephaly      Pachygyria      
 Hydranencephaly    Porencephaly   Abnormality of corpus callosum   




NAD.58. Was a lumbar puncture performed:  Yes   No  Unknown  NAD.59. (date: _____/_____/_____)   
NAD.60. Toxoplasmosis infection:        Negative   Positive    Unknown 
NAD.61. Cytomegalovirus infection:     Negative    Positive    Unknown 
NAD.62. Herpes Simplex infection:  Negative    Positive    Unknown 
NAD.63. Rubella infection:                   Negative    Positive    Unknown 
NAD.64. Syphillis infection:        Negative    Positive    Unknown 
NAD.65. Other tests/results/diagnosis (include dates): 
Health Department Information 
NAD.66. Name of person completing form: ________________________________________________ 
NAD.67. Phone:  _______________     
NAD.68. Email: ________________________  NAD.69. Date of form completion _____/_____/____ 
FOR INTERNAL CDC USE ONLY 
Mother ID:     State/territory ID: 
 
Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and 
maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information 
unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to 







Appendix 3 – N. Fowleri Talking Points with Edits 
 
Primary Amebic Meningoencephalitis (PAM) caused by Naegleria fowleri 
Talking Points 
 Naegleria fowleri is a commonly and naturally found amoeba in warm freshwater 
environments world wide 
o Lakes, rivers, hot springs, poorly maintained or under chlorinated swimming 
pools, and soil 
o Infections are most common during the summer months of July, August, 
and September 
 
 In rare cases it can travel up the nose and into the brain, causing primary amebic 
meningoencephalitis (PAM), which is often fatal 
o Usually from underwater submersion or other water-related activities that 
force water up the nose (e.g., swimming underwater, diving) 
o People do not get Naegleria infections by drinking contaminated water 
 
 It very rarely causes infections; less than 10 cases have been reported annually 
for the past 53 years in the United States 
 
 No approved treatment available 
o Miltefosine may help and is available from the CDC. 
 
 Symptoms begin 1 to 9 days after swimming underwater or nasal exposure to 
warm freshwater 
o Symptoms: headache, fever, nausea, vomiting, stiff neck; in later disease 
stages – confusion, lack of attention to surroundings or people, loss of 
balance and bodily control, seizures, hallucinations, and death 
o Death usually occurs within 5 days after symptoms appear 
 According to the Centers for Disease Control and Prevention (CDC), the only 
known way to prevent Naegleria infections is to refrain from water-related activities.  
However, some measures that might reduce risk by limiting the chance of 
contaminated water going up the nose include:  
o Avoid water-related activities in warm freshwater during periods of high 
water temperature and low water levels.  
o Hold the nose shut or use nose clips when taking part in water-related 
activities in bodies of warm freshwater.  
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o Avoid digging in or stirring up the sediment while taking part in water-related 
activities in shallow, warm freshwater areas.  
o If you are irrigating, flushing, or rinsing your sinuses (for example, by using 
a neti pot), use water that has been: 
 distilled;  
 sterilized;  
 previously boiled for 1 minute (at elevations above 6,500 feet, boil 
for 3 minutes) and left to cool;  
 or filtered, using a filter with an absolute pore size of 1 micron or 
smaller.  
 Rinse the irrigation device after each use with water that has been 
distilled, sterilized, filtered, or previously boiled and leave the device 
open to air dry completely. 
 
For additional information:  http://www.cdc.gov/parasites/naegleria/ 
Frequently Asked Questions 
What is Naegleria? 
Naegleria fowleri is a microscopic amoeba found in warm bodies of water worldwide. 
These freshwater bodies of water include lakes, rivers, and hot springs. It can also be 
found in soil, industrial water waste, and underchlorinated swimming pools. N. fowleri 
cannot live in salt water. It very rarely infects humans. 
What temperatures put water at risk for Naegleria? 
Naegleria fowleri enjoys warm temperatures. It grows best at high temperatures up to 
115°F (46°C) and is less likely to be found in the water as temperatures decline below 
77°F (25°C). Waters with total chlorine levels above 0.5mg/L also have decreased N. 
fowleri risk. Infection is most common during the summer months of July, August, and 
September. 
How common are Naegleria infections? 
Naegleria fowleri infections are extremely rare. There have been less than 10 cases 
reported annually for the past 53 years. 
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From 2006 to 2015, 37 infections were reported in the U.S. Of those cases, 33 people 
were infected by exposure to recreational water, three people were infected after 
performing nasal irrigation using tap water and one person was infected by tap water used 
on a backyard slip-n-slide.  
How does Naegleria cause disease? 
Naegleria fowleri causes disease in humans when it enters the body through the nose. 
This occurs when water is forced up the nose usually during warm freshwater activities 
such as swimming or diving. The amoeba travels from the nose to the brain, where it 
feeds on brain tissue and can cause primary amebic meningoencephalitis (PAM). The 
infection cannot be spread from person-to-person. One cannot be infected from drinking 
water.  
What are the symptoms of Naegleria fowleri infection? 
Symptoms generally start 1 to 9 days after swimming or nasal exposure to the amoeba 
in warm water. Initial signs include headache, fever, nausea, and stiff neck. Later signs 
include confusion, lack of attention to surroundings, loss of balance, loss of bodily control, 
seizures, hallucinations, and death. The disease progresses rapidly and usually results 
in death within 5 days once symptoms begin. Unfortunately, infection is almost always 
fatal.  
How is Naegleria treated? 
Treatment is aimed at reducing brain swelling and other supportive care. There are no 
approved drugs although several are being tested in laboratories. There have been 
reported survivals after treatment with miltefosine. A clear treatment plan is still unclear.  
Where are people most at risk? 
People are most at risk in the southern United States during summer months if they swim 
or dive in freshwater sites (such as lakes, rivers, or hot springs). Infections do occur 
worldwide. Bodies of water are most at risk when temperatures are hot and water levels 
are low. 
How can people protect themselves? 
According to the Centers for Disease Control and Prevention (CDC), the only known way 
to prevent Naegleria infections is to refrain from water-related activities.  However, some 
measures that might reduce risk by limiting the chance of contaminated water going up 
the nose include:  
• Avoid water-related activities in warm freshwater during periods of high water 
temperature and low water levels.  
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• Hold the nose shut or use nose clips when taking part in water-related activities in 
bodies of warm freshwater.  
• Avoid digging in or stirring up the sediment while taking part in water-related 
activities in shallow, warm freshwater areas.  
• If you are irrigating, flushing, or rinsing your sinuses (e.g. by using a neti pot), use 
water that has been: 
o distilled;  
o sterilized;  
o previously boiled for 1 minute (at elevations above 6,500 feet, boil for 3 
minutes) and left to cool;  
o or filtered, using a filter with an absolute pore size of 1 micron or smaller.  
o Rinse the irrigation device after each use with water that has been distilled, 
sterilized, filtered, or previously boiled and leave the device open to air dry 
completely. 
 
For additional information:  http://www.cdc.gov/parasites/naegleria/ 
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North Carolina FAQ 
How common is Naegleria fowleri in North Carolina? 
There have only been four cases of primary amebic meningoencephalitis (PAM) reported 
to the CDC from North Carolina. Two cases were in 1991, one case in 1998, and one 
case in 2003. This is a fairly low percentage of the total number of cases (37) reported 
across the nation to the CDC in the past ten years. N. fowleri infections are extremely 
rare.  
Where does the US National Whitewater Center water come from? 
The US National Whitewater Center draws its water from permitted well water supply and 
from the Charlotte-Mecklenburg water supply. 
Is it safe to go in the water at US National Whitewater Center? 
The risk associated with Naegleria fowleri at US National Whitewater Center is presumed 
equal to the risk of swimming in any freshwater body of water in the United States or 
abroad. N. fowleri is an extremely rare infection, but there is always a risk due to how 
commonly it is found in nature. The only way to truly limit infection is to abstain from all 
water activities in warm, freshwater bodies of water (including lakes, hot springs, and 
rivers). See the aforementioned safety measures to help reduce risk.  
The risk associated with Naegleria fowleri at the US National Whitewater Center is still 
being determined by the CDC and state health departments. At this time it is presumed 
equal to or greater than the risk of swimming in any freshwater body of water in the United 
States and individuals should take appropriate precautions. The only way to truly prevent 
infection is to abstain from all water activities in warm, freshwater bodies of water. 
What should you do if you were exposed (water up the nose) at US National 
Whitewater Center? 
First and foremost remain calm as the likelihood of contracting an infection is very low. 
Cases almost always occur in isolation; more than one person rarely gets sick at the same 
place and time. The risk associated with Naegleria fowleri at US National Whitewater 
Center is presumed equal to the risk of swimming in any freshwater body of water in the 
United States or abroad.  If you experience symptoms such as headache, fever, nausea, 
and stiff neck within 9 days of water exposure, then seek medical aid from your doctor. 
Be sure to include your concerns about Naegleria fowleri and your involvement in water 
activities. If it has been more than nine days since your visit to the National Whitewater 
Center and you are free of the symptoms of Naegleria, you are unlikely to be infected with 
N. fowleri.  
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Is the case associated with the US National Whitewater Center being investigated? 
Yes. The Mecklenburg County Health Department is collaborating with the NC Division 
of Public Health, the Ohio Department of Health and the Centers for Disease Control and 
Prevention to investigate the case.  
I participated in the rafting at the WWC at the same time as teen who died, what 
should I do? 
If you experience symptoms such as headache, fever, nausea, and stiff neck within 9 
days of water exposure, then seek medical aid from your doctor. Be sure to include your 
concerns about Naegleria fowleri and your involvement in water activities.  If it has been 
more than nine days since your visit to the National Whitewater Center and you are free 
of the symptoms of Naegleria, you are unlikely to be infected with N. fowleri. 
I went underwater (at WWC, or lake, or river) and now I feel sick, what should I do? 
If you experience symptoms such as headache, fever, nausea, and stiff neck within 9 
days of water exposure, then seek medical aid from your doctor. Be sure to include your 
concerns about Naegleria fowleri and your involvement in water activities. If it has been 
more than nine days since your visit to the National Whitewater Center and you are free 
of the symptoms of Naegleria, you are unlikely to be infected with N. fowleri. 
I went underwater (at WWC, or lake or river) and am well, should I see a doctor? 
No.  
I went underwater, am well but would like to be tested?  How can I get tested? 
Testing for Naegleria fowleri involves a lumbar puncture to obtain spinal fluid. It is not 
recommended that people without symptoms get tested.  
Can I take a vaccine or medicine to prevent this infection? 
No. 
Should the WWC close? 
No.  The risk associated with Naegleria fowleri at US National Whitewater Center is 
presumed equal to the risk of swimming in any freshwater body of water in the United 
States or abroad. N. fowleri is an extremely rare infection, but there is always a risk due 
to how commonly it is found in nature. The only way to truly limit infection is to abstain 
from all water activities in warm, freshwater bodies of water (including lakes, hot springs, 
and rivers). 
Is the water at the WWC rafting venue as safe as a public pool? 
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The water at the WWC is not considered a pool and therefore does not have to be 
inspected and cleaned in the same manner as a pool. 
What is the risk of exposure underwater at WWC rafting, lake or river? 
The risk is very low, but not zero.  Naegleria fowleri can be found in natural bodies of 
water, excluding saltwater.  Infection causing illness from Naegleria fowleri is very rare.  
There have only been 4 cases reported from NC to CDC in the past 25 years.  There 
have been 37 cases in the past 10 years nationally. 
The risk of exposure underwater at WWC is still undetermined, but is presumed to be 
equal or greater than risk found at natural bodies of freshwater. 
 
Possible Future questions: 
Since the test result were negative on the water samples taken at the WWC, does 
that mean I am safe to participate in rafting at the WWC? 
Negative results mean that the organism was not found in the sample taken.  The risk 
associated with Naegleria fowleri at US National Whitewater Center is presumed equal 
to the risk of swimming in any freshwater body of water in the United States or abroad. 
N. fowleri is an extremely rare infection, but there is always a risk due to how commonly 
it is found in nature.  
Since the test results were positive on the water samples taken at the WWC, can I 
safely participate in rafting at the WWC? 
Naegleria fowleri is a commonly found amoeba in warm bodies of freshwater word wide.  
The US National Whitewater Center is presumed equal to the risk of swimming in any 
freshwater body of water in the United States or abroad. 
I am immunosuppressed (or pregnant), is it more risky for me to participate in 
rafting at the WWC or go under at river or lake? 
Probably not. Primary amebic meningoencephalitis (PAM), the illness caused by 
Naegleria fowleri, typically affects young, healthy people. 
 
For additional information:  http://www.cdc.gov/parasites/naegleria/ 
 
 
 
